Biotechnology Assets (XMAD:BST) Institutional Ownership: 0.09% (As of Jul. 08, 2026)


XMAD:BST Biotechnology Assets SA XMAD:BST
22 GF Score
Price €0.21
GF Value €0.30
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Biotechnology Assets Institutional Ownership?

Biotechnology Assets XMAD:BST -0.93% 22 Institutional Ownership is 0.09% as of Jul. 08, 2026. GuruFocus rates XMAD:BST with a GF Score™ of 22/100 and a GF Value™ of €0.30 (Modestly Undervalued). The stock has 3 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Biotechnology Assets's institutional ownership is 0.09%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Biotechnology Assets's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Biotechnology Assets's Float Percentage Of Total Shares Outstanding is 0.00%.

Biotechnology Assets Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Biotechnology Assets's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biotechnology Assets Institutional Ownership Chart

Biotechnology Assets Historical Data

The historical data trend for Biotechnology Assets can be seen below:

2025-07-31 2025-08-31 2025-09-30 2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30
Institutional Ownership 0.10 0.10 0.10 0.10 0.10 0.10 0.10 0.09 0.09 0.09
XMAD:BST
22GF Score
Biotechnology Assets SA XMAD:BST
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biotechnology Assets Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 0.09% mean?
Biotechnology Assets (XMAD:BST) has a Institutional Ownership of 0.09% as of Jul. 08, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Biotechnology Assets and its competitors.
Is Biotechnology Assets' Institutional Ownership too high?
Biotechnology Assets' current Institutional Ownership is 0.09%. Overall, Biotechnology Assets has a GF Score™ of 22/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Biotechnology Assets' Institutional Ownership compare to VRTX and REGN?
Biotechnology Assets' Institutional Ownership of 0.09% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Biotechnology Assets and its competitors. Biotechnology Assets's current Institutional Ownership is 0.09%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biotechnology Assets stock overvalued right now?
Based on GuruFocus' analysis, Biotechnology Assets (XMAD:BST) is currently considered Modestly Undervalued. The stock's GF Value™ is €0.30, compared to a current price of €0.21 — trading 28.7% below its estimated fair value. The current Institutional Ownership is 0.09%. Biotechnology Assets' overall GF Score™ is 22/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Biotechnology Assets (XMAD:BST), the current Institutional Ownership is 0.09% as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Biotechnology Assets (XMAD:BST) Overvalued in 2026?

Based on GuruFocus' analysis, Biotechnology Assets stock appears to be undervalued. The current stock price of €0.21 is trading 28.7% below its estimated GF Value™ of €0.30. GuruFocus considers Biotechnology Assets to be Modestly Undervalued.

Key valuation signals for XMAD:BST:

  • Institutional Ownership: 0.09%
  • GF Value™: €0.30 vs. price of €0.21 (28.7% below fair value)
  • GF Score™: 22/100 with 3 warning signs

No single metric tells the full story. See the XMAD:BST stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Biotechnology Assets Business Description

Address Avenida del Desarrollo Tecnologico, No. 11, Scientific and Technological Park, Jerez de la Frontera, ESP, 11591
Biotechnology Assets SA is a clinical-stage biopharmaceutical company developing and producing biological products for the pharmaceutical and veterinarian sectors. It specializes in the prevention and treatment of niche diseases, such as orphan disease, antigens for new-generation vaccines, feed additives, and probiotics. Adl Bionatur offers a portfolio of non-therapeutic and therapeutic products to tier 1 and tier 2 animal health companies. The company's pipeline products include BNT006, BNT007, BNT010, and others.
22GF Score

Get the complete analysis for XMAD:BST

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.21
Price
€0.30
GF Value